Manila Times Business
Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules
SHANGHAI, June 24, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules, which were approved by the National Medical Products Administration (NMPA) in December 2025.
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Japan says that China has detained 2 of its citizens suspected of smuggling banned items
2h ago
Allied Biofuels Signs FEED + Detailed Engineering Contract with Rollover to EPC with Sinopec Engineering Group for US$6.1 Billion SAF and e-SAF Project in Uzbekistan
2h ago
Continuation of the implementation of Atos Group’s refinancing strategy
2h ago
EliteClouds.com - Why the Smart AI Play Is Selling Shovels, Not Digging for Gold
2h ago